OSTEVE 70 Tablets

What is OSTEVE 70

OSTEVE 70 contains Alendronic acid (as sodium alendronate), a bisphosphonate used to treat or prevent osteoporosis in postmenopausal women and in men at increased risk of fractures. Osteoporosis is a condition characterized by weak and brittle bones, often resulting from aging, hormonal changes, or prolonged steroid use.

• Each tablet contains 70 mg of Alendronic acid.
• Used for bone diseases, especially postmenopausal osteoporosis and corticosteroid-induced osteoporosis.
• Helps in maintaining bone density and reducing the risk of spine and hip fractures.

It works by preventing the breakdown of bone by inhibiting osteoclast-mediated bone resorption, thereby improving bone strength over time.

How to use OSTEVE 70

Proper administration is essential for effectiveness and minimizing side effects, particularly gastrointestinal ones.

• Take one tablet once a week on the same day each week.
• Swallow the tablet whole with a full glass (200 ml) of plain water.
• Do not lie down or recline for at least 30 minutes after taking the tablet and until after your first food of the day.
• Take it on an empty stomach, at least 30 minutes before eating, drinking (except water), or taking other medications or supplements.
• If a dose is missed, take it the next morning. Never take two tablets on the same day.

Adhering to these instructions helps avoid irritation of the esophagus and ensures maximum absorption.

Mode of Action OSTEVE 70

Alendronic acid in OSTEVE 70 is a nitrogen-containing bisphosphonate that acts by inhibiting osteoclast-mediated bone resorption.

• Binds to hydroxyapatite found in bone, especially at sites of active resorption.
• Inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway.
• This inhibition prevents osteoclasts from attaching to bone surfaces and forming ruffled borders, leading to reduced bone turnover.
• Results in increased bone mineral density and decreased fracture risk.

Its effects on bone turnover begin within weeks and are maintained with consistent weekly dosing.

OSTEVE 70 Interactions OSTEVE 70

OSTEVE 70 may interact with various drugs and nutrients, affecting its absorption or increasing the risk of side effects.

• Calcium, magnesium, iron supplements, or antacids: Can interfere with absorption if taken concurrently. Take at least 30 minutes after OSTEVE 70.
• NSAIDs (e.g., ibuprofen, naproxen): Concurrent use may increase the risk of gastrointestinal irritation.
• Aspirin or corticosteroids: May enhance risk of GI ulcers and irritation.
• Proton pump inhibitors: Long-term use may impair calcium absorption, reducing OSTEVE 70’s effectiveness.

Always inform your doctor about all medications and supplements you’re taking before starting OSTEVE 70.

Dosage of OSTEVE 70

The typical dosage is:

• One 70 mg tablet once weekly, usually taken on the same day each week.
• For postmenopausal women and men with osteoporosis.
• Must be taken in the morning with a full glass of water, 30 minutes before any food, drink, or other medication.

The duration of treatment depends on individual response, usually reassessed after 3–5 years. Regular bone mineral density tests may guide therapy continuation or cessation.

Possible side effects of OSTEVE 70

Like all medications, OSTEVE 70 may cause side effects, although not everyone experiences them.

• Common:
  • Gastrointestinal issues (nausea, abdominal pain, dyspepsia)
  • Musculoskeletal pain (joint, bone, or muscle pain)
• Less Common:
  • Esophageal irritation or ulceration
  • Headache or dizziness
• Rare:
  • Osteonecrosis of the jaw, especially after dental surgery
  • Atypical femoral fractures with long-term use
  • Severe allergic reactions (rash, angioedema)

Seek medical help if severe side effects or signs of allergic reaction occur.

OSTEVE 70 Contraindications OSTEVE 70

OSTEVE 70 should not be used in the following cases:

• Hypersensitivity to Alendronate or any excipients in the formulation.
• Esophageal abnormalities that delay esophageal emptying (e.g., strictures, achalasia).
• Inability to sit or stand upright for at least 30 minutes.
• Hypocalcemia – must be corrected before starting OSTEVE 70.
• Severe renal impairment (creatinine clearance <35 mL/min).

Consult a physician before starting if any of these apply or if other chronic conditions exist.

Storage of OSTEVE 70

Proper storage ensures drug stability and efficacy.

• Store at room temperature between 15°C and 30°C (59°F to 86°F).
• Keep in the original blister pack to protect from moisture and light.
• Do not refrigerate or freeze.
• Keep out of reach and sight of children.
• Do not use after the expiry date printed on the packaging.

Discard any unused medicine responsibly as per local regulations or pharmacy guidance.